Intensity Therapeutics Q2 EPS $(0.79) Misses $(0.40) Estimate.
Portfolio Pulse from vijay@benzinga.com
Intensity Therapeutics reported Q2 losses of $(0.79) per share, missing the analyst consensus estimate of $(0.40) by 97.5 percent.
August 14, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intensity Therapeutics' Q2 earnings per share of $(0.79) missed the consensus estimate of $(0.40) by 97.5%.
Intensity Therapeutics reported a larger than expected loss for Q2, missing the consensus estimate by a significant margin. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100